Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Wilde

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 2010
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075Stefani Spranger, Miran Javorovic, Maja Bürdek, et al.
Blood|July 10, 2009
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional aviditySusanne Wilde, Daniel Sommermeyer, Bernhard Frankenberger, et al.
Blood|February 29, 2012
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivoStefani Spranger, Irmela Jeremias, Susanne Wilde, et al.
Cancers|April 23, 2022
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor ReactivityNadja Sailer, Ina Fetzer, Melanie Salvermoser, et al.
Journal of Innate Immunity|December 24, 2010
The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretionMonika Braun, Bernadette Müller, Dominik ter Meer, et al.
Cancer Research|May 24, 2017
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell TherapyRamona Schlenker, Luis Felipe Olguín-Contreras, Matthias Leisegang, et al.
World Journal of Urology|July 6, 2005
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cellsBernhard Frankenberger, Sybille Regn, Christiane Geiger, et al.
Gastroenterology|June 9, 2015
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in MiceChristina Dargel, Michal Bassani-Sternberg, Julia Hasreiter, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyRichard A Morgan, Nachimuthu Chinnasamy, Daniel Abate-Daga, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 2010
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075Stefani Spranger, Miran Javorovic, Maja Bürdek, et al.
Blood|July 10, 2009
Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional aviditySusanne Wilde, Daniel Sommermeyer, Bernhard Frankenberger, et al.
Blood|February 29, 2012
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivoStefani Spranger, Irmela Jeremias, Susanne Wilde, et al.
Cancers|April 23, 2022
T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor ReactivityNadja Sailer, Ina Fetzer, Melanie Salvermoser, et al.
Journal of Innate Immunity|December 24, 2010
The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretionMonika Braun, Bernadette Müller, Dominik ter Meer, et al.
Cancer Research|May 24, 2017
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell TherapyRamona Schlenker, Luis Felipe Olguín-Contreras, Matthias Leisegang, et al.
World Journal of Urology|July 6, 2005
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cellsBernhard Frankenberger, Sybille Regn, Christiane Geiger, et al.
Gastroenterology|June 9, 2015
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in MiceChristina Dargel, Michal Bassani-Sternberg, Julia Hasreiter, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 5, 2013
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapyRichard A Morgan, Nachimuthu Chinnasamy, Daniel Abate-Daga, et al.
Pageof 2